|
12 Companies |
|
5 Products |
|
5 Products |
|
8 Mechanisms of Action |
|
0 Trials |
|
18 News |
|
- ||||||| Nucala (mepolizumab) / GSK
Trial completion: Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control (clinicaltrials.gov) - Jun 20, 2016
P3, N=556, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed
- ||||| Nucala (mepolizumab) / GSK
Enrollment closed: Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control (clinicaltrials.gov) - Dec 5, 2015
P3, N=544, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Cinqair (reslizumab) / Merck (MSD), UCB, Teva
Trial termination: Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma (clinicaltrials.gov) - Feb 19, 2015
P3, N=1051, Terminated, Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; Business decision
- |||||| Nucala (mepolizumab) / GSK
Enrollment open: Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control (clinicaltrials.gov) - Dec 24, 2014
P3, N=544, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Terminated; Business decision Not yet recruiting --> Recruiting
- |||||||||| Nucala (mepolizumab) / GSK
New P3 trial: Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control (clinicaltrials.gov) - Nov 3, 2014
P3, N=544, Not yet recruiting, Sponsor: GlaxoSmithKline
- Trial initiation date: The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia (clinicaltrials.gov) - Sep 22, 2014
P4, N=50, Completed, Sponsor: Hamamatsu University
Not yet recruiting --> Recruiting Initiation date: Jun 2007 --> Jun 2008
- |||| Cinqair (reslizumab) / Merck (MSD), UCB, Teva
Trial primary completion date: Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma (clinicaltrials.gov) - Jul 27, 2014
P3, N=1052, Active, not recruiting, Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
Initiation date: Jun 2007 --> Jun 2008 Trial primary completion date: Feb 2014 --> Dec 2014
- ||||||| Cinqair (reslizumab) / Merck (MSD), UCB, Teva
Trial completion: A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma (clinicaltrials.gov) - Mar 2, 2014
P3, N=315, Completed, Sponsor: Cephalon
Trial primary completion date: Feb 2014 --> Dec 2014 Active, not recruiting --> Completed
- Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Enrollment change: SPIRA: Small Particle Steroids in Refractory Asthma (clinicaltrials.gov) - Jan 29, 2014
P4, N=30, Completed, Sponsor: University of Nottingham
Active, not recruiting --> Completed N=40 --> 30
- Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Trial completion: SPIRA: Small Particle Steroids in Refractory Asthma (clinicaltrials.gov) - Jan 29, 2014
P4, N=30, Completed, Sponsor: University of Nottingham
N=40 --> 30 Recruiting --> Completed
- ||||| Cinqair (reslizumab) / Merck (MSD), UCB, Teva
Enrollment closed: Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma (clinicaltrials.gov) - Jan 12, 2014
P3, N=1052, Active, not recruiting, Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- |||| Fasenra (benralizumab) / AstraZeneca
Trial completion: A Phase IIa Study of KHK4563 (clinicaltrials.gov) - Jan 5, 2014
P2a, N=106, Completed, Sponsor: Kyowa Hakko Kirin Company, Limited
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Cinqair (reslizumab) / Merck (MSD), UCB, Teva
Trial completion: Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma (clinicaltrials.gov) - Nov 12, 2013
P3, N=510, Completed, Sponsor: Teva Pharmaceutical Industries
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Dupixent (dupilumab) / Sanofi, Regeneron
Enrollment change: Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma (clinicaltrials.gov) - Nov 7, 2012
P2, N=104, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed N=130 --> 104
- |||| Dupixent (dupilumab) / Sanofi, Regeneron
Trial completion: Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma (clinicaltrials.gov) - Nov 7, 2012
P2, N=104, Completed, Sponsor: Sanofi
N=130 --> 104 Active, not recruiting --> Completed
- |||||||||| Cinqair (reslizumab) / Merck (MSD), UCB, Teva
New P3 trial: Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma (clinicaltrials.gov) - Jan 10, 2012
P3, N=510, Completed, Sponsor: Teva Pharmaceutical Industries
- Trial completion: The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia (clinicaltrials.gov) - Sep 5, 2011
P4, N=50, Completed, Sponsor: Hamamatsu University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Fasenra (benralizumab) / AstraZeneca
New P2a trial: A Phase IIa Study of KHK4563 (clinicaltrials.gov) - Aug 7, 2011
P2a, N=106, Completed, Sponsor: Kyowa Hakko Kirin Company, Limited